Ophthalmic Drugs 2017

SMi’s Ophthalmic Drugs will be taking place in just 3 weeks at the Copthorne Tara Hotel in London, Kensington UK. Network with top pharma companies are joining us including Boehringer Ingelheim, Bayer, Envisia Therapeutics, NightstaRx, Shire, Novaliq GmbH and more. www.ophthalmicdrugs.com/phpr

Here’s a rundown of popular sessions being presented:

1. Development of a Lentiviral Vector Platform for the Treatment of Chronic Ocular Disease
Day 1 | 28th November 2017 | @11:00

Speaker: Yatish Lad, Senior Manager, Early Development Group, Oxford BioMedica

This presentation will introduce the LentiVector® platform for gene and cell therapy, enable to experience translating from preclinical studies to First-in-Man clinical trials and explore current challenges and future goals.

Summary of presentation:

– Introduction to the LentiVector® platform.
– Experience in translating from preclinical studies to First-in-Man clinical trials.
– Demonstration of long-term clinical gene expression in patients with advanced wet age-related macular degeneration.
– Current challenges and future goals.

2. Novel Endpoints in Ophthalmic Clinical Trials
Day 1 | 28th November 2017 | @15:20

Speaker: Aniz Girach, Chief Medical Officer, NightstaRx.

Get stuck in with NightstaRx as they examine how to measure each key endpoint in a certain timescale, explore the pros and cons of these and gain a deeper understanding by hearing from regulators as they provide their feedback on these endpoints.

Summary of presentation:

– What are the key endpoints being explored now and in the future?
– What are the advantages and disadvantages of each key endpoint?
– Regulators’ feedback is relating to these endpoints.
– What endpoints are realistically measurable in the timescale?

3. Aqueous, Preservative-Free Ocular Drug Delivery Technology with Unique Properties
Day 1 | 28th November 2017 | @14:10

Speaker: Bernhard Guenther, Co-Founder, Chief Innovation Officer, Novaliq GmbH

One of the biggest challenges currently facing the pharmaceutical industry is the development of more efficient drug delivery systems. For instance, the anterior part of the eye is amongst the most readily accessible organs, in terms of location in the human body; however, drug delivery to eye tissue is particularly problematic. This is reflected by the notoriously poor bioavailability of topical ocular drug formulations of 5% or less.*

Summary of presentation:

– EyeSol Technology.
– Non-aqueous, preservative-free.
– Poorly soluble drugs.
– Ophthalmic drug delivery.

4. Non-Invasive Therapies for Diabetic Macular Oedema and Non-Proliferative Diabetic Retinopathy
Day 2 | 29th November 2017 | @11:00

Speaker: Victor Chong, Global Head of Ophthalmology, Boehringer Ingelheim

During Victor’s presentation, he will explore non-invasive therapies for diabetic macular oedema and non- proliferative diabetic retinopathy. The solutions for these diseases will be examined, including light and laser therapy and oral therapies as well as the use of steroids.

Summary of presentation:

– Current gold standard – anti-VEGF / steroids /conventional laser.
– Oral therapy for DME.
– Oral therapy for NPDR.
– Light and laser therapy for DME.

5. New Technologies in Ophthalmic Drug Delivery
Day 2 | 29th November 2017 | @15:20

Speaker: Matthias Birkhoff, Vice President Business Development, Aptar Pharma

Poor Patient Compliance is a major impediment to effective treatments in eye care. By bringing in new technologies will help ease the situation and enable patients to become comfortable during treatment. Also, monitoring systems for clinical trials are a revolutionary method to ease work of clinicians and make clinical data more reliable. Other factors to be discussed are the novel drug delivery systems and how they can contribute to patient adherence, which have been approved by the FDA.

Summary of presentation:

– Poor patient compliance is a major impediment to effective treatments in eye care.
– Preservatives are often associated with negative side effects and consequently do affect patient adherence.
– Novel drug delivery systems can contribute to patient adherence and have even been approved by the FDA.
– Monitoring systems for clinical trials are a revolutionary method to ease work of clinicians and make clinical data more reliable.

Companies Attending:

Santen Inc, Shire, Novartis, Roche, NightstaRx, Aerie Pharmaceuticals, Bayer, Envisia Therapeutics, Boehringer Ingelheim, Oxford BioMedica, Novaliq GmbH, Alimera Sciences, Aptar Pharma and PharmaMedic Consultancy Ltd and more.

Booked Last Week:

Abdi Ibrahim Pharma, Annexin Pharmaceuticals AB, Biozep AS, Fresenius Kabi, MHRA, Nanoptima and Roche.

Further information is available at: www.ophthalmicdrugs.com/phpr

For those looking to attend there are currently special rates available. Book online or get in touch.

SMi Presents the Launch of…

Ophthalmic Drugs
Date: 28th – 29th November 2017
Location: Kensington, London
Website: www.ophthalmicdrugs.com/phpr

Sponsored by: Leica Microsystems | Experimentica

—end—

Contact Information:

For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk